SKYE BIOSCIENCE, INC. (SKYE) CLASS ACTION DEADLINE APPROACHING: Berger Montague Advises Investors to Inquire About a Securities Fraud Class Action by January 16, 2026

Core Viewpoint - A class action lawsuit has been filed against Skye Bioscience, Inc. for allegedly misleading investors regarding the prospects of its lead candidate, nimacimab, during the Class Period from November 4, 2024, to October 3, 2025 [1][2]. Company Overview - Skye Bioscience, Inc. is a clinical-stage biotechnology company based in San Diego, focusing on developing treatments for obesity and metabolic diseases [2]. Legal Proceedings - The lawsuit claims that throughout the Class Period, the company misled investors about the potential success of nimacimab [2]. - Investors reportedly became aware of the misleading information on October 6, 2025, when Skye announced that nimacimab failed to meet its primary weight-loss endpoint in a Phase 2a trial, leading to a significant stock price drop of approximately 60%, closing at $1.90 [3]. Investor Information - Investors who purchased Skye securities during the Class Period have until January 16, 2026, to seek appointment as lead plaintiff representatives [2].